Back to Journals » Journal of Hepatocellular Carcinoma » Call For Papers

Journal of Hepatocellular Carcinoma

ISSN: 2253-5969

The following Article Collection/ Thematic Series is currently open for submissions:

The Dynamic Landscape of Liver Transplantation and Hepatocellular Carcinoma

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Dynamic Landscape of Liver Transplantation and Hepatocellular Carcinoma" in the Journal of Hepatocellular Carcinoma.

There has been an ongoing evolution of the role of liver transplantation in the treatment of patients who have a diagnosis of hepatocellular carcinoma over the last four decades. From the beginnings of the Milan criteria to the use of liver transplantation as a salvage therapy for patients who have exhausted other medical and surgical interventions, we are living in a field that is rapidly changing. Newer immunotherapies and incorporating a multi-faceted approach to treat this disease subsequently expands the potential pool of patients who may ultimately require and will subsequently benefit from liver transplantation. Unfortunately the ongoing shortage of donor livers (both deceased and living) plays a role in the availability of liver transplantation as a treatment option. The impact of these therapies on liver transplant outcomes are intertwined and with the field rapidly growing it is important to look at the current state from a research and translational perspective. The following subjects fit within this call for papers:

  • Salvage liver transplantation
  • Pre-transplant immunotherapies
  • Post-transplant HCC recurrence and treatment options
  • Role of living donor liver transplant and HCC
  • Portal vein tumor thrombus and liver transplantation

Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 15 September 2024

Please submit your manuscript on our website, quoting the promo code PMOQM to indicate that your submission is for consideration in this Article Collection. Standard article publishing charges apply.

Guest advisor

David Gerber, Christian R. Holmes Memorial Chair of Surgery and Chair of the Department of Surgery, University of Cincinnati College of Medicine

Dr. Gerber received his medical degree from the University of Pittsburgh and completed general surgery training at Emory University in Atlanta, GA with a post-doctoral fellowship in Transplantation Immunology. He subsequently completed his clinical transplant fellowship at the Starzl Transplantation Institute at the University of Pittsburgh School of Medicine. Clinically he has expertise in solid organ transplantation with a focus on liver cancer including the integration of navigation into minimally invasive surgery procedures.

Dr. Gerber has received over 25 basic science grants including extramural funding from the National Institutes of Health, the American Liver Foundation, the Roche Organ Transplant Research Foundation, the American Society of Transplant Surgeons, and the American College of Surgeons. He has been principal investigator or co-investigator of more than 40 industry-sponsored clinical trials focusing on advancing patient outcomes in hepatocellular carcinoma and transplantation. He has published over 200 peer reviewed publications, peer-reviewed abstracts and book chapters in the areas of liver cancer, transplantation, stem cell biology, and regenerative medicine. In addition, he has received two patents and has given over 100 national and international presentations in healthcare and biotechnology.

View all papers in this article collection

Call For Papers

Editor-in-Chief: Dr Ahmed Kaseb

To see where the Journal of Hepatocellular Carcinoma is indexed online view the Journal Metrics.

Call for Papers: Addressing global differences in HCC risk factors and management strategies

The Journal of Hepatocellular Carcinoma is encouraging papers addressing global diversity in HCC risk factors and their effect on outcomes. Although significant advances have been made in multidisciplinary and individualized screening and treatments for HCC, such sophisticated methods are relatively expensive and therefore remain beyond the reach of many patients in less economically developed countries where local resources and healthcare budget are limited. To address the global differences in treatment provision, the journal Editors are seeking to publish multidisciplinary clinical and translational studies, cost-effective screening and treatment strategies and consensus statements, including those which consider available local resources.
Authors interested in publishing country-specific guidelines and conference proceedings may be eligible for a discounted publication processing fee. Such requests will be assessed on a case-by-case basis. Please contact Sophie Fagg at [email protected] with your query prior to submission.

What is the advantage to you of publishing in the Journal of Hepatocellular Carcinoma?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although the Journal of Hepatocellular Carcinoma receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. The Journal of Hepatocellular Carcinoma has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
The Journal of Hepatocellular Carcinoma is indexed on PubMed Central (title abbreviation J Hepatocell Carcinoma). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Ahmed Kaseb
Journal of Hepatocellular Carcinoma

Email: Editor-in-Chief